Rudolf Uher

Trans-ancestry genome-wide association meta-analysis of antidepressant response to selective serotonin reuptake inhibitors in clinical studies of depression

This study performs a trans-ancestry GWAS of SSRI response in depression, finding suggestive associations and enrichment in serotonergic pathways but no genome-wide significant variants.

Meta-analysis of CYP2C19 and CYP2D6 metabolic activity on antidepressant response from 13 clinical studies using genotype imputation

This study examines the association between CYP2C19 and CYP2D6 metabolic phenotypes and antidepressant response using genotype imputation across 13 studies, finding no significant associations after correction for multiple testing.

Genetic structure of major depression symptoms across clinical and community cohorts

This study identifies genetic subtypes of major depressive symptoms by analyzing data from clinical and community cohorts, finding distinct factors for appetite/weight symptoms and missing data patterns.

Novel polygenic risk score links depression-related cortical transcriptomic changes to brain morphology and symptom severity

This paper develops a transcriptome-based polygenic risk score (T-PRS) linking depression-related cortical gene expression changes to brain morphology and symptom severity in MDD.

A polygenic predictor of treatment-resistant depression using whole exome sequencing and genome-wide genotyping

The paper develops a polygenic predictor for treatment-resistant depression using whole exome sequencing and genome-wide genotyping, finding that genetic scores combined with clinical factors improve prediction.

Minimal phenotyping yields GWAS hits of reduced specificity for major depression

This paper shows that GWAS using minimal phenotyping for depression identifies non-specific genetic factors shared with other psychiatric conditions, not specific to major depressive disorder.

Genetic variation in the Major Histocompatibility Complex and association with depression

This study investigates whether genetic variation in the Major Histocompatibility Complex (MHC) is associated with depression risk, finding no significant associations at a conservative threshold.

Polygenic risk scores for major depressive disorder and neuroticism as predictors of antidepressant response: meta-analysis of three treatment cohorts.

This study evaluates polygenic risk scores for MDD and neuroticism as predictors of antidepressant response across three cohorts, finding no significant prediction but consistent directional effects.

Effect of cytochrome CYP2C19 metabolizing activity on antidepressant response and side effects: meta-analysis of data from genome-wide association studies

This paper conducts a meta-analysis showing that CYP2C19 poor metabolizers have better antidepressant efficacy but similar side effects compared to extensive metabolizers.

Assessing 42 inflammatory markers in 321 control subjects and 887 major depressive disorder cases: BMI and other confounders and overall predictive ability for current depression

The paper evaluates 42 inflammatory markers in MDD cases and controls, finding strong confounding effects and limited predictive power of individual markers for MDD diagnosis.

New insights on the pharmacogenomics of antidepressant response from the GENDEP and STAR*D studies: rare variant analysis and high-density imputation

This study identifies two SNPs associated with antidepressant response in GENDEP and STAR*D studies but finds limited replication in independent cohorts.

Pharmacogenetics of antidepressant response: a polygenic approach

This study investigates whether polygenic risk scores (PRS) can predict antidepressant response in MDD, finding no significant predictive effect.